🇺🇸 FDA
Patent

US 9388189

Pyrrolotriazinone derivatives as PI3K inhibitors

granted A61KA61K31/53A61K45/06

Quick answer

US patent 9388189 (Pyrrolotriazinone derivatives as PI3K inhibitors) held by Almirall, S.A. expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Almirall, S.A.
Grant date
Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/53, A61K45/06, A61P, A61P1/04